Poly Medicure has secured a stay from the Delhi High Court on the operation and execution of a stamp duty order dated June 15, 2026. The stay remains effective until the next date of hearing, providing temporary relief to the company regarding the demand raised by the Office of Collector of Stamps, Revenue Department, Government of NCT of Delhi.

The writ petition challenging the impugned order was listed for hearing on July 3, 2026. During the proceedings, no representation appeared on behalf of the respondent, prompting the court to grant the stay. Poly Medicure received the official copy of the court order on July 7, 2026.

This development follows the company's initial disclosure made on June 16, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing had informed the exchanges about the orders passed by the stamp duty authorities.

Key Dates

Poly Medicure has confirmed its growth outlook across both domestic and international business segments, signaling a positive trajectory for the company's operations. The medical devices manufacturer expects approximately 20% growth for its domestic business, while targeting international business growth in the range of 15-16%.

Growth Expectations at a Glance

The company's management has outlined distinct growth expectations for its two key business segments. The following table summarizes the confirmed growth targets:

Domestic Business Outlook

Poly Medicure has confirmed a growth expectation of approximately 20% for its domestic business. This reflects the company's confidence in the strength of its home market operations and demand for its product portfolio within India.

International Business Outlook

On the international front, Poly Medicure expects its global business to grow in the range of 15-16%. This projection underscores the company's continued focus on expanding its presence across international markets and sustaining export-driven revenue streams.